1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > GABA Receptor Agonists -Pipeline Insights, 2016

GABA Receptor Agonists -Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “GABA Receptor Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the GABA Receptor Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for GABA Receptor Agonists. DelveInsight’s Report also assesses the GABA Receptor Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of GABA Receptor Agonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the GABA Receptor Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for GABA Receptor Agonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

GABA Receptor Agonists -Pipeline Insights, 2016

- GABA Receptor Agonists Overview
- GABA Receptor Agonists Disease Associated
- GABA Receptor Agonists Pipeline Therapeutics
- GABA Receptor Agonists Therapeutics under Development by Companies
- GABA Receptor Agonists Filed and Phase III Products
- Comparative Analysis
- GABA Receptor Agonists Phase II Products
- Comparative Analysis
- GABA Receptor Agonists Phase I and IND Filed Products
- Comparative Analysis
- GABA Receptor Agonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- GABA Receptor Agonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- GABA Receptor Agonists - Discontinued Products
- GABA Receptor Agonists - Dormant Products
- Companies Involved in Therapeutics Development for GABA Receptor Agonists
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for GABA Receptor Agonists by Therapy Area, 2016
- Number of Products under Development for GABA Receptor Agonists, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- GABA Receptor Agonists Assessment by Monotherapy Products
- GABA Receptor Agonists Assessment by Combination Products
- GABA Receptor Agonists Assessment by Route of Administration
- GABA Receptor Agonists Assessment by Stage and Route of Administration
- GABA Receptor Agonists Assessment by Molecule Type
- GABA Receptor Agonists Assessment by Stage and Molecule Type
- GABA Receptor Agonists Therapeutics - Discontinued Products
- GABA Receptor Agonists Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for GABA Receptor Agonists by Therapy Area, 2016
- Number of Products under Development for GABA Receptor Agonists, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- GABA Receptor Agonists Assessment by Monotherapy Products
- GABA Receptor Agonists Assessment by Combination Products
- GABA Receptor Agonists Assessment by Route of Administration
- GABA Receptor Agonists Assessment by Stage and Route of Administration
- GABA Receptor Agonists Assessment by Molecule Type
- GABA Receptor Agonists Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.